---
title: "Immuron soars 57% on exclusive US distribution deal for digestive device PROIBS"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298070284.md"
description: "Immuron (IMRN) soars 57% in regular trading to $1.74 after securing exclusive US distribution rights for Calmino's PROIBS device."
datetime: "2026-09-04T19:49:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298070284.md)
  - [en](https://longbridge.com/en/news/298070284.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298070284.md)
generator: "portal-rs"
---

# Immuron soars 57% on exclusive US distribution deal for digestive device PROIBS

Immuron(IMRN.US) 盘中涨近**57%**，现报**1.74 美元**。

公司近日宣布与 Calmino group AB 达成独家分销协议，获得 PROIBS 在美国市场的独家分销权。PROIBS 是一款针对消化健康的医疗器械，旨在缓解腹痛和肠道问题，该产品已在欧洲上市超过十年，并在可用性研究中获得积极反馈。此举将 Immuron 的商业版图拓展至规模达**41.6 亿美元**的美国肠道健康市场。

### Related Stocks

- [IMRN.US](https://longbridge.com/en/quote/IMRN.US.md)

## Related News & Research

- [Immuron To Launch PROIBS In U.S. After Australia Debut; Pre-market Shares Up](https://longbridge.com/en/news/298028882.md)
- [Immuron to launch PROIBS® in the United States | IMRN Stock News](https://longbridge.com/en/news/298022732.md)
- [Immuron FY26 net sales rise 6% to AUD 7.7 million](https://longbridge.com/en/news/297303231.md)
- [Immuron posts CEO presentation for TechKnow Invest Roadshow](https://longbridge.com/en/news/293928783.md)
- [Immuron Stock Surges Friday: What's Driving the Action?](https://longbridge.com/en/news/298044643.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**